Top Story

Follow these thought leaders tweeting on healthcare big data (Weekend Rounds)

A review of life science current events reported by MedCity News this week: 5 healthcare big data Twitter users to follow.  Spend a little while following the #bigdata hashtag on Twitter and you won’t hear a lot about healthcare. Instead, those looking to stay up on the latest healthcare big data buzz would do better […]

A review of life science current events reported by MedCity News this week:

5 healthcare big data Twitter users to follow.  Spend a little while following the #bigdata hashtag on Twitter and you won’t hear a lot about healthcare. Instead, those looking to stay up on the latest healthcare big data buzz would do better to follow the #healthdata hashtag.

Do wellness incentive plans really reduce costs? The researchers examined the results from a wellness program run by one of Germany’s largest insurers and found that participants in the program had “significantly” lower costs than those who didn’t participate. The average difference between the two groups was $251 per year, but that number drops to $143 when wellness program costs are factored in.

GSK melanoma combination drug takes on Roche’s Zelboraf in phase 3 trials. GSK has started a phase 3 study of its drug in melanoma patients. Besides studying its combination drug against a placebo, GSK will also do a head-to-head study against the Roche product.

Why one VC thinks now’s a great time to be a healthcare investor. In the Q&A below, Ted Driscoll talks about how federal health reform has changed his approach to investing and why he hasn’t been a very active investor in the mobile health space.

Device maker growing without sales force, VCs, plans to be a game changer. This company does things a little differently. It doesn’t employ a sales force, advertise its products or exhibit at trade shows. Although it incubates startups in-house, it’s not trying to be a game changer. Its CEO — who “loves” audits because they’re like free consulting — didn’t even have a business plan for the first several years of the company’s existence. He says no to customers sometimes. He’s never tapped into venture capital and makes it clear he has no intention of divesting or selling off equity in the company.